151 related articles for article (PubMed ID: 36427171)
1. Risk of thrombosis in women with cancer undergoing controlled ovarian hyperstimulation for fertility preservation.
Melo VD; Liseth OY; Schmidt WM; Pruthi RK; Marshall AL; Shenoy CC
J Assist Reprod Genet; 2022 Dec; 39(12):2847-2856. PubMed ID: 36427171
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
[TBL] [Abstract][Full Text] [Related]
3. Risk of thrombosis in women with malignancies undergoing ovarian stimulation for fertility preservation.
Somigliana E; Peccatori FA; Filippi F; Martinelli F; Raspagliesi F; Martinelli I
Hum Reprod Update; 2014; 20(6):944-51. PubMed ID: 25013217
[TBL] [Abstract][Full Text] [Related]
4. COH outcomes in breast cancer patients for fertility preservation: a comparison with the expected response by age.
Malacarne E; Devesa M; Martinez F; Rodriguez I; Coroleu B
J Assist Reprod Genet; 2020 Dec; 37(12):3069-3076. PubMed ID: 32945994
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
[TBL] [Abstract][Full Text] [Related]
6. Arterial and venous complications after fertility treatment: A French nationwide cohort study.
Filipovic-Pierucci A; Gabet A; Deneux-Tharaux C; Plu-Bureau G; Olié V
Eur J Obstet Gynecol Reprod Biol; 2019 Jun; 237():57-63. PubMed ID: 31009860
[TBL] [Abstract][Full Text] [Related]
7. Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers.
Goldrat O; Van Den Steen G; Gonzalez-Merino E; Dechène J; Gervy C; Delbaere A; Devreker F; De Maertelaer V; Demeestere I
Reprod Biol Endocrinol; 2019 Jan; 17(1):3. PubMed ID: 30606204
[TBL] [Abstract][Full Text] [Related]
8. Ovarian tissue cryopreservation can be combined simultaneously with oocyte retrieval after controlled ovarian hyperstimulation.
Puy V; Dupeux M; Mayeur A; Grynberg M; Benoit A; Bendayan M; Zhegari F; Hesters L; Gallot V; Prevot S; Frydman N; Sonigo C
Hum Reprod; 2023 May; 38(5):860-871. PubMed ID: 36860186
[TBL] [Abstract][Full Text] [Related]
9. Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols.
Balkenende EME; Dahhan T; Beerendonk CCM; Fleischer K; Stoop D; Bos AME; Lambalk CB; Schats R; Smeenk JMJ; Louwé LA; Cantineau AEP; de Bruin JP; Linn SC; van der Veen F; van Wely M; Goddijn M
Hum Reprod; 2022 Jul; 37(8):1786-1794. PubMed ID: 35776109
[TBL] [Abstract][Full Text] [Related]
10. Risk of ovarian hyperstimulation syndrome in women with malignancies undergoing treatment with long-acting gonadotropin-releasing hormone agonist after controlled ovarian hyperstimulation for fertility preservation: a systematic review.
Ingold C; Navarro PA; de Oliveira R; Barbosa CP; Bedoschi G
Ther Adv Reprod Health; 2023; 17():26334941231196545. PubMed ID: 37674690
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Oocyte and Embryo Quality Between Random Start and Controlled Ovarian Stimulation Cycles in Cancer Patients Undergoing Fertility Preservation.
İsrafilova G; Şükür YE; Özkavukcu S; Sönmezer MA; Atabekoğlu CS; Özmen B; Berker B; Aytaç R; Koç A; Sönmezer M
Reprod Sci; 2021 Aug; 28(8):2200-2207. PubMed ID: 33409878
[TBL] [Abstract][Full Text] [Related]
12. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
[TBL] [Abstract][Full Text] [Related]
13. Ovarian response to stimulation for fertility preservation in women with hematologic cancer.
Brun T; Dion L; Jaillard S; Bales D; Domin M; Lavoué V; Levêque J; Houot R; Duros S
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101925. PubMed ID: 33010467
[TBL] [Abstract][Full Text] [Related]
14. Differential impact of controlled ovarian hyperstimulation on live birth rate in fresh versus frozen embryo transfer cycles: a Society for Assisted Reproductive Technology Clinic Outcome System study.
Gerber RS; Fazzari M; Kappy M; Cohen A; Galperin S; Lieman H; Jindal S; Buyuk E
Fertil Steril; 2020 Dec; 114(6):1225-1231. PubMed ID: 33012553
[TBL] [Abstract][Full Text] [Related]
15. Ovarian hyperstimulation syndrome and thrombotic events.
Mor YS; Schenker JG
Am J Reprod Immunol; 2014 Dec; 72(6):541-8. PubMed ID: 25146913
[TBL] [Abstract][Full Text] [Related]
16. Timing of ovarian stimulation in patients prior to gonadotoxic therapy: an analysis of 684 stimulations.
von Wolff M; Capp E; Jauckus J; Strowitzki T; Germeyer A;
Eur J Obstet Gynecol Reprod Biol; 2016 Apr; 199():146-9. PubMed ID: 26927896
[TBL] [Abstract][Full Text] [Related]
17. Random-start controlled ovarian hyperstimulation with letrozole for fertility preservation in cancer patients: case series and review of literature.
Keskin U; Ercan CM; Yilmaz A; Babacan A; Korkmaz C; Duru NK; Ergun A
J Pak Med Assoc; 2014 Jul; 64(7):830-2. PubMed ID: 25255597
[TBL] [Abstract][Full Text] [Related]
18. Is ovarian hyperstimulation associated with higher blood pressure in 4-year-old IVF offspring? Part I: multivariable regression analysis.
Seggers J; Haadsma ML; La Bastide-Van Gemert S; Heineman MJ; Middelburg KJ; Roseboom TJ; Schendelaar P; Van den Heuvel ER; Hadders-Algra M
Hum Reprod; 2014 Mar; 29(3):502-9. PubMed ID: 24365797
[TBL] [Abstract][Full Text] [Related]
19. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
20. Maximize the safety and efficacy of fertility preservation by random start/dual ovarian stimulation for early breast cancer patients.
Young SR; Chang YE; Yang WV; Lu BJ; Chou SY; Chen CH
Taiwan J Obstet Gynecol; 2023 Mar; 62(2):330-333. PubMed ID: 36965903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
